A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Financial Summary
| Share Statistics | QCLS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $21.3 | $569.9 | 10% |
|
| Shares Out (Mil) | 8.1 | 44.8 | 18% |
|
| Institutional Ownership | 89.2% | 84.6% | 57% |
|
| Float (Mil) | 7.8 | 45.1 | 16% |
|
| Beta | 2.14 | 0.67 | 94% |
|
| Avg Daily Volume (000s) | 197 | 294 | 45% |
|
| Price Change (52-week) |
(82.5%) | 65.2% | 6% |
|
| Growth | QCLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (4.1%) | (2.0%) | 35% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | QCLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $230 | na |
|
| Net Income (TTM) (Mil) | ($12) | ($11) | 28% |
|
| EPS (TTM) | ($6.054) | ($0.600) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($6) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $22 | $493 | 11% |
|
| Valuation | QCLS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.03 | 2.89 | 24% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | QCLS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | (0.2%) | na |
|
| ROA | (41.2%) | (25.5%) | 14% |
|
| ROE | (80.7%) | (21.4%) | 11% |
|
| Liabilities to Assets | 38.1% | 35.5% | 29% |
|
| F-Score | 3 | 3 | 19% |
|
Q/C Technologies, Inc. did not pass any screens on 7/30/2026.
